| 4.94 -0.53 (-9.69%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.8 | 1-year : | 7.95 |
| Resists | First : | 5.82 | Second : | 6.8 |
| Pivot price | 4.78  |
|||
| Supports | First : | 4.26 | Second : | 3.29 |
| MAs | MA(5) : | 4.96 |
MA(20) : | 4.55 |
| MA(100) : | 4.38 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 64.3 |
D(3) : | 65.2 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 8.78 | Low : | 2.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AVR ] has closed below upper band by 39.9%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.51 | 5.51 - 5.53 |
| Low: | 4.85 - 4.89 | 4.89 - 4.91 |
| Close: | 4.89 - 4.94 | 4.94 - 4.99 |
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Wed, 17 Dec 2025
Anteris Technologies Global Corp. (NASDAQ:AVR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tue, 16 Dec 2025
Stephen Denaro Resigns from Anteris Board - The Globe and Mail
Mon, 15 Dec 2025
Anteris Technologies Global Corp. $AVR Shares Sold by L1 Capital Pty Ltd - MarketBeat
Mon, 15 Dec 2025
Stephen Denaro resigns from Anteris Technologies Global Corp. board - Investing.com
Mon, 15 Dec 2025
Anteris Technologies Global Corp. Announces Board Resignation - TradingView — Track All Markets
Tue, 09 Dec 2025
FDA Approves Anteris Technologies’ DurAVR THV Global Trial - Medical Product Outsourcing
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | -52 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.12e+007 (%) |
| Held by Institutions | 3.843e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.45e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.6 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 189.9 % |
| Return on Equity (ttm) | -269 % |
| Qtrly Rev. Growth | 698.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -8.481e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.91 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.53e+006 |
| Forward Dividend | 1.22e+006 |
| Dividend Yield | 30971700% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|